FAQ 36-4: Dermatology

© 2026 by Data Trace Publishing Company. All rights reserved. Reproduction or translation of any part of this work beyond that permitted by Section 107 or 108 of the United States Copyright Law without the permission of the copyright owner is unlawful. No portion(s) of the work(s) may be reproduced without written consent from Data Trace Publishing Company. Permission to reproduce copies of articles for non-commercial use may be obtained for a fee of $22 per copy from the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400, www.copy right.com. The ideas and opinions expressed in Foot and Ankle Quarterly are those of the authors and do not necessarily reflect those of the Editor or the Publisher. Publication of an advertisement or other product mentioned in Foot and Ankle Quarterly should not be construed as an endorsement of the product of the manufacturer’s claims. Readers are encouraged to contact the manufacturer with any questions about the features or limitations of the products mentioned. The Publisher does not assume any responsibility for any injury and/or damage to any persons or property arising out of or related to any use of the material contained in this periodical. The reader is advised to check the
appropriate medical literature and the product information currently provided by the manufacturer of each device or of each drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other healthcare professionals, relying on independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient.

Disclosure

Data Trace Publishing Company Continuing Education Mission Statement

Data Trace Publishing Company is committed to providing high-quality print and internet-based enduring continuing education programs, including lectures, feature articles, and condensations and commentaries on current clinical podiatric topics and medical risk management topics which lead to improved delivery of patient care and help reduce the potential for medical errors. These programs are provided to meet the educational needs of the podiatric medical profession and thereby enhance the quality of patient care.

Program Objectives

Foot and Ankle Quarterly (FAQ) is a unique program designed to help today’s podiatric physician manage an ever-increasing flow of information. After completing the Foot and Ankle Quarterly, Volume 36 program, the learner should be better able to: develop and refine a perspective on current treatment recommendations, updates, and advances pertinent to podiatric practice; evaluate the implications of the learned information as it pertains to the diagnosis and treatment of podiatric disorders and societal issues and barriers, and; apply current trends, standards, and best practices into learner’s own practice.

Data Trace Publishing Company Continuing Education Accreditation Statement

Data Trace Publishing Company is approved by the Council on Podiatric Medical Education (CPME) as a provider of continuing education in podiatric medicine. Data Trace Publishing Company has approved this activity for a maximum of 6 continuing education contact hours (CECHs). Physicians should claim only the contact hours commensurate with the extent of their participation in the activity.

Estimated time to complete activity: 6 hours
Date of release: January 30, 2026
Expiration Date: January 30, 2029 (unless further validated and extended by provider). For amended dates of activity expiration, please see FAQ Activity Effective Dates at www.datatrace.com).

Commercial Interests

No commercial interest provided financial support for this continuing education activity.

CECH Note

Participants of Volume 36, Issue 4 will receive a max- imum of 6 CECHs for a correctly-completed CME Answer Form submitted to Data Trace Publishing Company for scoring. In order to qualify for CECHs, a score of 70% or more must be achieved on the writ- ten examination material. Any participant who does not pass the first time may take the exam one additional time (within 90 days of receipt of results). A new test must be submitted to Data Trace Publishing Company with a fee of $15. Data Trace Publishing Company will score the tests and notify participants of their scores within 30 days. You will be responsible for notifying your state of the number of contact hours you have received. Participants are requested to complete a course evaluation for use in developing future issues and to meet the unique educational needs of podiatric physicians.

FINANCIAL DISCLOSURE INFORMATION

It is the policy of Data Trace Publishing Company to ensure balance, independence, objectivity, and scientific rigor in all of its educational programs. All faculty, presenters, speakers, authors, and reviewers participating in any programs provided by Data Trace Publishing Company are expected to disclose any relevant financial relationships with CPME-defined commercial interests to the program audience. “Relevant financial relationships” are financial relationships of the individual (including those of the individual’s spouse or partner) in any amount occurring within the past 12 months that create a conflict of interest. A commercial interest is any organization manufacturing, producing, marketing, re-selling, or distributing healthcare goods or services consumed by or used on patients. The CPME mandates that the content of accredited activities be objective and independent of commercial bias. The intent of this policy is that readers may form their own judgements about the presentations, using independent review to resolve all identified conflicts of interest.

In addition to disclosing commercial relationships, faculty are advised of the following policies: Each continuing education planner and author has submitted a Conflict of Interest Disclosure in order to identify relevant financial relationships and resolve conflicts.

Limitations on Data: Presenter will ensure, to the ex tent possible, meaningful disclosure of limitations on data (e.g., ongoing research, interim analyses, preliminary data, or unsupported opinion).

Discussion of Unapproved Uses: If unapproved (unlabeled) uses are discussed during the continuing education activity, the presenter will disclose when a product is not approved in the United States (and/or the nation where the activity takes place) for the use under discussion.

Data Trace Publishing Company has identified the option to disclose as follows:

The following authors have disclosed whether they or a member of their immediate family:

1. Will be receiving an honorarium for this activity
2. Within the past 12 months, had a financial or other significant relationship with a commercial organization that markets a product to which they will refer as speaker or author:
   1. Received monetary or other significant research support
   2. Are or had been a paid consultant
   3. Are or had been a full-time or part-time employee
   4. Are or had been a paid or unpaid member of an advisory or similar board
   5. Are or had been a member or on the Board of Trustees
   6. Other
3. Within the past 12 months, had a financial or other significant relationship with a commercial organization that markets a product to which they will refer as speaker or author, BUT will not be recommending any of their products over similar competitor products
4. Within the past 12 months, had a financial or other significant relationship with a commercial organization that markets a product to which they will refer as speaker or author, AND will be recommending one or more of their products over similar competitor products. Recommendation will be based on:
   1. Exclusively on data and/or clinical experience not generated by the manufacturer or derived from manufacturer-sponsored studies
   2. Data and/or clinical experience most of which were not generated by the manufacturer or derived from manufacturer-sponsored studies
   3. Data and/or clinical experience, most of which were generated by the manufacturer or derived from manufacturer-sponsored studies
   4. Exclusively on data and/or clinical experience generated by the manufacturer or derived from manufacturer or derived from manufacturer-sponsored studies
   14. Have no conflicts to disclose

Article Authors and Lecturers

• Darrell R. Latva (n.)
• Paul Lucas (n.)
• Jasmine Rana (1. Data Trace Publishing Co)
• Ashka Trivedi (n.)
• Tracey C. Vlahovic (1. Data Trace Publishing Co)
• Qeena C. Woodard (n.)
• Martin Yorath (n.)

FAQ Journal Planning Committee

• Chrissy Wesolowski (n.)
• Lauren Molander (n.)
• Stephanie Wu, DPM, MSc (n.)

Foot and Ankle Quarterly
36-4 Contributors

Guest Editor

Tracey C. Vlahovic, DPM, FFPM, RCPS (Glasg)
Professor, Samuel Merritt University College of Podiatric Medicine, Oakland, CA

Contributors

Darrell R. Latva, DPM, FACFAS, FACPM
Associate Professor, Dr. William M. Scholl College of Podiatric Medicine at Rosalind Franklin University, North Chicago, IL; Diplomate, American Board of Foot and Ankle Surgery and American Board of Podiatric Medicine

Paul Lucas, DPM, FACFAS

Jasmine Rana, MD
Dermatologist, Overlake Hospital Clinics, Bellevue, WA

Ashka Trivedi, DPM
Assistant Professor, Department of Medicine and Science, Rosalind Franklin University of Medicine and Science, North Chicago, IL

Qeena C. Woodard, DPM, DPM, MHPE, FACPM, FACFAS
Associate Dean of Clinical Experiences, Associate Professor, Podiatric Medicine and Surgery Department, Rosalind Franklin University, North Chicago, IL

Martin Yorath, DPM, FACFAS, FACPM, FFPM, RCPS (Glasgow)
Medical Director (Retired), Rosalind Franklin University Health Clinics, North Chicago, IL